• For individuals between the ages of 1-45 years with a first-degree relative (parent, child, sibling) with type 1 diabetes
• For individuals between the ages of 1-20 years with a second-degree relative (grandparent, aunt, uncle, niece, nephew, cousin or half-sibling) with type 1 diabetes

Purpose: To identify individuals at-risk for T1D and offer close monitoring for disease progression as well as potential prevention study opportunities.

For more information visit TrialNet on the web. 

Study Contact:  Juanita O'Brian, jobrian@usf.edu or (813) 974-9817

• For individuals > 6 years
• Positive for two or more diabetes-related auto-antibodies
• Normal Glucose Tolerance

Purpose:  To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Contact: Emily Eyth, MSN, RN, CDE  emilyeyth@usf.edu or (813) 974-2793

• For individuals > 3 years old
• Positive for two or more diabetes-related auto-antibodies
• Normal Glucose Tolerance

Purpose: To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Contact: Emily Eyth, MSN, RN, CDE emilyeyth@usf.edu or (813) 974-2793

• For individuals > 12 years old
• Diagnosed with Type 1 Diabetes within 150 days

Purpose: To preserve insulin production by preventing beta cell destruction in individuals newly diagnosed with T1D.

Study Contact: Emily Eyth, MSN, RN, CDE emilyeyth@usf.edu or (813) 974-2793

• For individuals ages 18-40 years old
• Diagnosed with T1D within the last 5 years
• Not on a pump or willing to come off the pump for the study duration (up to 16 weeks).

Purpose: To evaluate the safety of an investigational drug called TOL-3021 and whether it could stop  the immune system from attacking the beta cells in the pancreas of adult with Type 1 diabetes, thus helping the pancreas make insulin.

Study Contact: Emily Eyth, MSN, RN, CDE emilyeyth@usf.edu or (813) 974-2793

• For Individuals ages 8-17
• Diagnosed with T1D within 42 days
• Up to date on immunizations

Purpose: To determine whether an investigational drug called Teplizumab may help preserve insulin production in children and adolescents who were recently diagnosed with Type 1 Diabetes

Study Contact: Ivette Morales, RN  imorale4@usf.edu  (813)-974-6139

• For Individuals ages 1-17
• Diagnosed with T1D ≥ 6 months
• Not currently wearing a pump or willing to go off a pump for the study duration (up to 31 weeks)

Purpose: To evaluate the efficacy of a new ultra-fast insulin compared to Humalog in pediatric patients with T1D

Study Contact: Ivette Morales, RN  imorale4@usf.edu (813)-974-6139

• For individuals ages 10-17
• Diagnosed with type 2 diabetes
• Additional eligibility criteria will be reviewed with you by the study coordinator

Purpose: To test the safety and effectiveness of Alogliptin (FDA approved for treatment of type 2 adults) in pediatric type 2 patients.

Study Contact: Emily Eyth, MSN, RN, CDE  emilyeyth@usf.edu or (813) 974-2793

• For individuals ages 10-17
• Diagnosed with type 2 diabetes for at least 12 weeks
• Additional eligibility criteria will be reviewed with you by the study coordinator

Purpose: To test the safety and effectiveness of Linagliptin in combination with Empagliflozin (FDA approved for treatment of type 2 adults) in pediatric type 2 patients.

Study Contact: Ivette Morales, RN  imorale4@usf.edu  or (813) 974-6139